BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 102 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2021. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,767,933 | -43.2% | 4,448,757 | 0.0% | 0.99% | -42.5% |
Q2 2023 | $22,466,223 | +244.7% | 4,448,757 | +29.0% | 1.72% | +280.3% |
Q1 2023 | $6,518,151 | +5.0% | 3,448,757 | 0.0% | 0.45% | +29.2% |
Q4 2022 | $6,207,763 | +6.5% | 3,448,757 | -0.0% | 0.35% | +19.9% |
Q3 2022 | $5,830,000 | -31.3% | 3,449,845 | 0.0% | 0.29% | -33.3% |
Q2 2022 | $8,487,000 | -11.2% | 3,449,845 | 0.0% | 0.44% | +58.0% |
Q1 2022 | $9,556,000 | -48.0% | 3,449,845 | 0.0% | 0.28% | -25.8% |
Q4 2021 | $18,388,000 | -37.0% | 3,449,845 | 0.0% | 0.37% | +7.2% |
Q3 2021 | $29,186,000 | -30.6% | 3,449,845 | 0.0% | 0.35% | -36.7% |
Q2 2021 | $42,054,000 | -49.8% | 3,449,845 | 0.0% | 0.55% | -70.8% |
Q1 2021 | $83,693,000 | -24.3% | 3,449,845 | 0.0% | 1.88% | -35.6% |
Q4 2020 | $110,568,000 | +6.0% | 3,449,845 | 0.0% | 2.92% | -33.9% |
Q3 2020 | $104,289,000 | -28.3% | 3,449,845 | 0.0% | 4.42% | -24.5% |
Q2 2020 | $145,445,000 | +69.0% | 3,449,845 | 0.0% | 5.85% | +30.0% |
Q1 2020 | $86,074,000 | – | 3,449,845 | – | 4.50% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Boxer Capital, LLC | 2,014,858 | $17,046,000 | 0.60% |
NEA Management Company, LLC | 3,449,845 | $29,186,000 | 0.35% |
MPM BioImpact LLC | 248,506 | $2,102,000 | 0.33% |
Artal Group S.A. | 1,646,517 | $13,930,000 | 0.31% |
RA Capital Management | 2,589,904 | $21,911,000 | 0.30% |
Bellevue Group AG | 3,463,000 | $29,297,000 | 0.30% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 760,128 | $6,431,000 | 0.13% |
Ikarian Capital, LLC | 150,484 | $1,272,000 | 0.09% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,000 | $371,000 | 0.09% |
Virtus ETF Advisers LLC | 16,600 | $140,000 | 0.06% |